Named on one round in the feed.
Since 2023-08-17
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $155M | 2023-08-17 | [ PART ] |